Cat. #160985
RGLI001-2 Brain cancer cell line
Cat. #: 160985
Unit size: 1/7 volume of T-175 flask/vial, 1 ml
Organism: Human
Tissue: Brain
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Medical-Industrial Translational Research Center
Institute: Fukushima Medical University
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: RGLI001-2 Brain cancer cell line
- Alternate name: RGLI001-2, RGLI1-2, RGLI1, RGLI001
- Cancer: Neurological cancer
- Cancers detailed: Brain neoplasms;Glioblastoma
- Research fields: Cancer
- Organism: Human
- Gender: Male
- Tissue: Brain
- Donor: 67 years old male patient
- Growth properties: Adherent
- Description: Novel patient-derived cell lines (PDCs) have been constructed under the Fukushima Translational Research Project. Our comparative histological and comprehensive gene expression analyses have shown that the characteristics of PDCs were similar to their source tumors, even after long-term growth in culture conditions
- Application: High-throughput screening, Xenograft model
- Biosafety level: 1
Applications
- Application: High-throughput screening, Xenograft model
Handling
- Format: Frozen
- Volume: 1 ml
- Growth medium: DMEM/F-12 with 10% heat-inactivated FBS
- Temperature: 37° C
- Atmosphere: 5% CO2
- Unit size: 1/7 volume of T-175 flask/vial, 1 ml
- Shipping conditions: Dry ice
- Storage medium: CELLBANKER 2
- Storage conditions: Liquid Nitrogen
- Mycoplasma free: Yes
- Characterisation tests: Pathogen and stelility test; Comprehensive gene expression analysis; Cancer panel sequencing; Whole exome sequencing; Anticancer drug susceptibility testing
